Up 36%, Is Eli Lilly Still a Buy?

Eli Lilly reported blockbuster growth driven by its weight-loss and diabetes franchise, with Q3 revenue up 54% year-over-year to $17.6 billion and Q3 diluted EPS rising from $1.07 in Q3 2024 to $6.21 in Q3 2025; net income was up 127% year-to-date through the first three quarters of 2025. Flagship product Mounjaro generated $15.55 billion in sales (up 94% YTD) and Zepbound accelerated to $9.28 billion from just over $3 billion a year earlier, prompting Lilly to raise full-year 2025 revenue guidance to $63.0–$63.5 billion (nearly 40% growth) and project full-year EPS of $21.80–$22.50 (implying a ~49.5x P/E on current pricing).

Analysis

Market structure: Eli Lilly (LLY) is capturing disproportionate share of a rapidly expanding GLP-1/GLP-1-RA market; winners include LLY (Mounjaro, Zepbound), CDMOs with peptide capacity, and diagnostics/weight-management service providers; losers are legacy obesity/diabetes drug sellers facing pricing pressure. The revenue guidance ($63–63.5B; implied 40% YoY) and current P/E (~49.5) imply the market expects sustained high single-digit-to-double-digit unit growth and pricing power for 3–5 years, tightening peptide supply-demand and raising bargaining power for manufacturers. Cross-asset: a large positive re-rating in LLY supports risk-on flows—IG credit spreads could tighten for large pharm names while equity vols for GLP-1 exposure should stay elevated; USD may see modest strength on risk-on but impact is secondary.

Risk assessment: Tail risks include aggressive payer coverage rollbacks or formulary exclusions, major safety signals from broad real-world use, or manufacturing disruption causing supply shortfalls; each could cut top-line by 20–40% in 6–12 months. Immediate (days) risk is earnings-driven volatility around the next report; short-term (weeks/months) is payer commentary and CMS coverage actions; long-term (years) is durability of patient demand and margin squeeze from competition. Hidden dependencies: growth depends on Mounjaro/Zepbound production scale-up, contracting with PBMs, and retention rates—churn >15% or supply lag would materially lower modeled CAGR. Key catalysts: upcoming earnings (next few weeks), CMS/payer policy updates (30–90 days), new label/safety data (0–12 months).

Trade implications: Direct: establish a controlled long exposure to LLY to capture continued category growth but size to 2–4% of portfolio given P/E ~50 and execution risk; prefer long-dated LEAPs to spread cost. Pair trades: long LLY / short NVO or broad biotech ETF (e.g., IBB) to express idiosyncratic outperformance; size 1–2% net. Options: buy Jan 2028 LLY LEAP calls ~10–20% OTM or buy a 2-year call spread to cap cost; sell near-term covered calls on existing exposure to monetize high IV. Sector rotation: increase overweight Healthcare (Large-cap pharma) by 1–2% funded by trimming cyclical discretionary and high-duration tech names.

Contrarian angles: Consensus underweights payer pushback and manufacturing constraints; the market may be underpricing a scenario where rapid demand meets supply ceilings and aggressive formulary management within 12–18 months. The 36% run-up may be partially overdone given a P/E near 50; a miss vs. guidance (revenue < $63B or EPS < $21.8) could trigger 20–30% downside in short order. Historical parallel: prior blockbuster drug ramps (e.g., Sovaldi) showed fast policy and pricing reactions—expect similar second-order regulatory and public-health scrutiny that could blunt multiple expansion.

Key Decisions for Investors

• Establish a 2–4% long position in Eli Lilly (LLY) using a mix of stock and LEAPs: allocate 60% to shares and 40% to Jan-2028 LEAP calls ~10–20% OTM to control capital; set a tactical sell/trim signal if reported full-year revenue < $63B or EPS guidance falls below $21.8 (cut position by 50%).
• Implement a relative-value pair: go long LLY (1–2% notional) and short NVO (Novo Nordisk) or IBB (1–2% notional) to isolate Lilly execution upside; rebalance if spread narrows by 15% or after the next two earnings cycles (6 months).
• Use options to manage near-term earnings risk: buy a Jan-2028 call spread (buy LEAP call ~10% OTM, sell higher strike ~30% OTM) sized to 1–2% portfolio notional; if implied volatility collapses post-earnings and stock drops >10%, add to underlying equity at P/E <40.
• Reduce cyclical equity exposure by 1–2% and redeploy to large-cap pharma CDS or IG pharma bonds selectively; tighten stop-loss on LLY core position to 12% to protect against rapid regulatory or safety-driven drawdowns.
• Actively monitor the next 30–90 days for three triggers before increasing size: (1) CMS/payer coverage statements, (2) manufacturing/supply announcements from LLY or major CDMOs, (3) any FDA safety communications—add incremental exposure only if none of these are negative and guidance is confirmed.